<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; competitive</title>
	<atom:link href="http://www.tapanray.in/tag/competitive/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>In the Age of AI, Why Emotional Intelligence Is the New Competitive Edge in Indian Pharma Marketing</title>
		<link>http://www.tapanray.in/in-the-age-of-ai-why-emotional-intelligence-is-the-new-competitive-edge-in-indian-pharma-marketing/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=in-the-age-of-ai-why-emotional-intelligence-is-the-new-competitive-edge-in-indian-pharma-marketing</link>
		<comments>http://www.tapanray.in/in-the-age-of-ai-why-emotional-intelligence-is-the-new-competitive-edge-in-indian-pharma-marketing/#comments</comments>
		<pubDate>Sun, 16 Nov 2025 06:32:16 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[advantage]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[Artificial]]></category>
		<category><![CDATA[competitive]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[edge]]></category>
		<category><![CDATA[emotional]]></category>
		<category><![CDATA[empathy]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Intelligence]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=11000</guid>
		<description><![CDATA[In today’s AI-driven world — where scientific excellence, product claims, and competitive pricing are no longer enough to differentiate pharmaceutical companies — Emotional Intelligence (EI) is rapidly emerging as the new strategic advantage in Indian pharma marketing. As doctors face shrinking time, patients demand &#8230; <a href="http://www.tapanray.in/in-the-age-of-ai-why-emotional-intelligence-is-the-new-competitive-edge-in-indian-pharma-marketing/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/in-the-age-of-ai-why-emotional-intelligence-is-the-new-competitive-edge-in-indian-pharma-marketing/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Continues ‘The Cat And Mouse Game’ In Pharma Business?</title>
		<link>http://www.tapanray.in/continues-the-cat-and-mouse-game-in-pharma-business/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=continues-the-cat-and-mouse-game-in-pharma-business</link>
		<comments>http://www.tapanray.in/continues-the-cat-and-mouse-game-in-pharma-business/#comments</comments>
		<pubDate>Mon, 24 Jun 2019 00:00:55 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Americans]]></category>
		<category><![CDATA[anti-trust]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[cat]]></category>
		<category><![CDATA[cat and mouse game]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[competitive]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[evade]]></category>
		<category><![CDATA[fixing]]></category>
		<category><![CDATA[Game]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[lawsuit]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[mouse]]></category>
		<category><![CDATA[ooff the cuff]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[pressure]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[price-fixing]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[standards]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[United States]]></category>
		<category><![CDATA[wrongdoing]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9601</guid>
		<description><![CDATA[Many are already aware of the critical factors that make generic drugs so important for patients &#8211; virtually for all. These don’t just facilitate greater access to health care &#8211; offering affordable alternatives to high-priced off-patent innovative drugs. This is &#8230; <a href="http://www.tapanray.in/continues-the-cat-and-mouse-game-in-pharma-business/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/continues-the-cat-and-mouse-game-in-pharma-business/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Will Global Pharma Majors be successful in their foray into highly competitive generics pharma business offering no (patent) protection of any kind?</title>
		<link>http://www.tapanray.in/will-global-pharma-majors-be-successful-in-their-foray-into-highly-competitive-generics-pharma-business-offering-no-patent-protection-of-any-kind/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=will-global-pharma-majors-be-successful-in-their-foray-into-highly-competitive-generics-pharma-business-offering-no-patent-protection-of-any-kind</link>
		<comments>http://www.tapanray.in/will-global-pharma-majors-be-successful-in-their-foray-into-highly-competitive-generics-pharma-business-offering-no-patent-protection-of-any-kind/#comments</comments>
		<pubDate>Mon, 05 Jul 2010 01:00:13 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[any]]></category>
		<category><![CDATA[be]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[cliff]]></category>
		<category><![CDATA[competitive]]></category>
		<category><![CDATA[emerging]]></category>
		<category><![CDATA[foray]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[highly]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[into]]></category>
		<category><![CDATA[kind]]></category>
		<category><![CDATA[majors]]></category>
		<category><![CDATA[markets]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[No]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[offering]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[successful]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[their]]></category>
		<category><![CDATA[Will]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=406</guid>
		<description><![CDATA[As reported by IMS Health, emerging markets will register a growth rate of 14% to 17% by 2014, when the developed markets will be growing by 3% to 6% during the same period. It is forecasted that the global pharmaceutical &#8230; <a href="http://www.tapanray.in/will-global-pharma-majors-be-successful-in-their-foray-into-highly-competitive-generics-pharma-business-offering-no-patent-protection-of-any-kind/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/will-global-pharma-majors-be-successful-in-their-foray-into-highly-competitive-generics-pharma-business-offering-no-patent-protection-of-any-kind/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>With significant competitive edge should Global Biotech Companies consider entry into high potential ‘Biosimilar drugs’ business?</title>
		<link>http://www.tapanray.in/with-significant-competitive-edge-should-global-biotech-companies-consider-entry-into-high-potential-biosimilar-drugs-business/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=with-significant-competitive-edge-should-global-biotech-companies-consider-entry-into-high-potential-biosimilar-drugs-business</link>
		<comments>http://www.tapanray.in/with-significant-competitive-edge-should-global-biotech-companies-consider-entry-into-high-potential-biosimilar-drugs-business/#comments</comments>
		<pubDate>Thu, 07 May 2009 01:30:20 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[competitive]]></category>
		<category><![CDATA[consider]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[edge]]></category>
		<category><![CDATA[efficacy]]></category>
		<category><![CDATA[entry]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[into]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[potential]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Should]]></category>
		<category><![CDATA[significant]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[with]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=895</guid>
		<description><![CDATA[‘Biosimilar drugs’ – rapid future growth potential: In most of the developed countries of the world, besides regulatory issues, ‘Biosimilar drugs’are considered a threat to the fast growing global biotech industry. However, many believe that innovative biotech companies can have &#8230; <a href="http://www.tapanray.in/with-significant-competitive-edge-should-global-biotech-companies-consider-entry-into-high-potential-biosimilar-drugs-business/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/with-significant-competitive-edge-should-global-biotech-companies-consider-entry-into-high-potential-biosimilar-drugs-business/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
